Company Description
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain.
Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression.
The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital.
NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Jonathan Javitt |
Contact Details
Address: 1201 Orange Street, Suite 600 Wilmington, Delaware 19801 United States | |
| Phone | 484 254 6134 |
| Website | nrxpharma.com |
Stock Details
| Ticker Symbol | NRXP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001719406 |
| CUSIP Number | 629444209 |
| ISIN Number | US6294442099 |
| Employer ID | 82-2844431 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew Patrick Duffy | Chief Business Officer and Co-Chief Executive Officer of Hope Therapeutics |
| Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chief Scientist Officer, Chairman and Interim Chief Executive Officer |
| Richard Clavano Narido | Treasurer |
| Michael S. Abrams | Chief Financial Officer |
| Dr. Riccardo Panicucci Ph.D. | Chief Manufacturing and Technology Officer |
| Suzanne Messere | Investor Relations |
| Dr. Philip T. Lavin Ph.D. | Chief Methodologist |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | 8-K | Current Report |
| Apr 17, 2025 | 424B3 | Prospectus |
| Mar 21, 2025 | 8-K | Current Report |
| Mar 14, 2025 | 10-K | Annual Report |
| Mar 7, 2025 | D | Notice of Exempt Offering of Securities |
| Feb 20, 2025 | 424B3 | Prospectus |
| Feb 3, 2025 | 8-K | Current Report |
| Jan 29, 2025 | 8-K | Current Report |
| Jan 29, 2025 | 424B3 | Prospectus |
| Jan 22, 2025 | 8-K | Current Report |